The B-cell lymphoma-6 (BCL6) gene was initially identified at a translocation site observed frequently in diffuse large B-cell lymphomas. In the present study, BCL6 mutations at the 5′ non-coding region in 47 cases of transitional call carcinoma (TCC) were analysed using polymerase chain reaction-single-strand conformation polymorphism. The results were compared with data obtained previously by immunohistochemical staining for the BCL6 protein. Overall, BCL6 mutations were observed in 44.7% of cases. Mutation of the 5′ non-coding region was not correlated with histological grade of the tumour; however, the better the histological grade, the greater the mutation rate of the E1.12 fragment. The BCL6 mutation occurred independently of over-expression of the protein. The BCL6 gene mutation and the protein expression were detectable in a large proportion of TCCs. BCL6 protein over-expression as well as BCL6 gene mutation of the E1.12 fragment may play an important role in the morphological differentiation of TCC.
Introduction
The B-cell lymphoma-6 (BCL6) gene was initially identified at the break-point of a chromosomal translocation involving 3q27, a translocation site observed frequently in diffuse large B-cell lymphomas (DLBLs). 1 Upon sequencing, the BCL6 gene was shown to encode a protein with six C-terminal zinc finger motifs of Kruppel-type transcription factors. 2 The BCL6 protein is highly expressed in normal germinal centre B-cells and has been identified in a variety of lymphoproliferative conditions, such as DLBL, follicular lymphoma, Burkitt's lymphoma, lymphocytepredominant Hodgkin's disease and some T-cell lymphomas. 3 -5 Rearrangements and/or mutations of the 5′ non-coding region of the BCL6 gene have been demonstrated in a large majority of DLBLs. 6, 7 Some, but not all, of these genetic alterations have been shown to lead to protein dysregulation. 4, 5, 8 Only a few reports have described the BCL6 gene mutation and its protein expression in organs other than lymphoid tissues. Yoshida et al. 9 and Kanazawa et al. 10 described the expression of BCL6 mRNA and BCL6 protein in HY Cho, HS Park, Z Lin et al. BCL6 in transitional cell carcinomas epidermal squamous cells. Kanazawa et al. 10 also described the expression of the BCL6 protein in a variety of epidermal neoplasms; these investigators suggested that BCL6 may play a role in morphological differentiation in normal and neoplastic epidermal cells. Recently, it was reported that the BCL6 protein was expressed in normal and malignant transitional epithelium, and that the expression rate was significantly increased in malignant epithelium. In addition, substantial expression of BCL6 protein had a negative correlation with the histological grade of the transitional cell carcinoma (TCC).
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In this study, the BCL6 gene mutation at the 5′ non-coding region was evaluated by polymerase chain reaction-single-stranded conformational polymorphism (PCR-SSCP) in order to determine the role of BCL6 in the differentiation of TCCs. The relationship between the BCL6 gene mutation and its protein expression in TCCs is also discussed.
Materials and methods

MATERIALS
A total of 47 cases of TCCs of the urinary bladder, kidney and urethra were selected from the pathology file at the Department of Pathology, Korea University Anam Hospital, Korea. The tissues were routinely processed by 10% buffered formalin fixation and embedded in paraffin. The haematoxylin-eosin-stained slides were retrieved and the appropriate blocks were selected for DNA extraction and immunohistochemical staining. Using the World Health Organization classification, the cases were classified into 19 cases of grade 1 tumour, 13 cases of grade 2 tumour and 15 cases of grade 3 tumour.
METHODS
In order to identify BCL6 gene mutations at the 5′ non-coding region, PCR-SSCP was performed. Genomic DNA was extracted from sections (10 µm) of formalin-fixed, paraffin-embedded tissues using a GNOME ® DNA Isolation Kit (BIO 101 Systems, Irvine, California, USA). Purified DNA was then quantified spectrophotometrically before PCR amplification. The 5′ non-coding region (fragments E1.10, 1.11 and 1.12) of the BCL6 gene was amplified by PCR using the following primers: E1.21B, 5′-CTCTTGCCAAATGCTTTG-3′ and E1.24, 5′-TAATTCCCCTCCTTCCTC-3′ (for fragment E1.10); E1.23, 5′-AGGAAGGAGGGGAATTAG-3′ and IP1.6, 5′-AAGCAGTTTGCAAGCGAG-3′ (for fragment E1.11); and IP1.7, 5′-TTCTCGCTTGCAAACTGC-3′ and E1.26, 5′-CACGATACTTCATCTCATC-3′ (for fragment E1.12). The PCR mix consisted of 150 ng DNA, 1 U Taq DNA polymerase, 0.2 mM deoxyribonucleoside triphosphates (dNTPs), 2 pmol each of primer and 10 × buffer in a total volume of 25 µl. Amplification was performed on a GeneAmp-PCR System 2400 (Perkin Elmer, Norwalk, Connecticut, USA) as follows: 40 cycles of denaturing at 94°C for 35 s, annealing at 50°C for 30 s for E1.10 and 55°C for 30 s for E1.11 and 1.12, with an extension at 72°C for 7 min. The PCR products were checked for yield and size on a 1.2% agarose gel before further analysis. The PCR product (2 µl) was loaded on a 12% polyacrylamide gel after denaturation by boiling for 3 min followed by quick chilling on ice. The samples were then subjected to electrophoresis at 100 V overnight. The gel was then fixed with 10% glacial acetic acid for 10 min, transferred into 1% nitric acid and soaked for 3 min. Subsequently, it was reacted with 0.2% silver nitrate solution for 20 min after washing with distilled water. The gel was again washed with distilled water, and developed with 0.28 M sodium carbonate and 0.019% formaldehyde until distinct bands were detected. Mutation For the immunohistochemical study, using a Dako LSAB™ kit (Dako, Glostrup, Denmark), tissue sections (4 µm) were deparaffinized and rehydrated. Endogenous peroxidase activity was eliminated by incubation with 3% H 2 O 2 in methanol for 15 min. The antigen was retrieved at 103 kPa for 2 min by placing the slides in 0.001 M EDTA (ethylenediaminetetraacetic acid) buffer (pH 8.0). The slides were then incubated with a primary monoclonal antibody for BCL6 (1:10; Dako) for 1 h at room temperature. After incubation with a biotinylated link for 30 min, the sections were incubated with a streptavidinperoxidase complex at room temperature for 30 min. Immunostaining was visualized using 3,3′-diaminobenzidine. The sections were counterstained with haematoxylin. As a negative control, 0.1 M Tris buffer (pH 7.6) replaced the primary antibody.
STATISTICAL ANALYSIS
The data were entered into an Excel ® spreadsheet (Microsoft, Redmond, WA, USA). SAS version 6.12 for Windows (SAS Institute, Cary, North Carolina, USA) was used for statistical evaluation. The relationship between the histological grade and BCL6 protein over-expression or gene mutation was evaluated using the Mantel-Haenszel χ 2 test. The relationship between BCL6 protein expression and BCL6 gene mutation was evaluated using the χ 2 test. P-values < 0.05 were considered to be statistically significant.
Results
BCL6 GENE MUTATION
The results are given in Table 1 . PCR-SSCP was performed on 47 TCCs, and 21 cases (44.7%) of BCL6 gene mutation were observed. A mutation band at the E1.11 fragment was observed in 13 cases (27.7%) and a mutation band at the E1.12 fragment was also observed in 13 cases (27.7%). However, a mutation band was not found at the E1.10 fragment. Although a BCL6 gene mutation at a 5′ non-coding region fragment was not correlated with the histological grade of TCCs, mutation of the E1.12 fragment had a negative correlation with the histological grade (P = 0.0086). Figure 1 shows mutation bands at the E1.11 and E1.12 fragments of the BCL6 gene.
BCL6 PROTEIN OVER-EXPRESSION
BCL6 protein over-expression (> 20% of cells) was observed in 21 of 47 (44.7%) TCCs (Table 1) . BCL6 protein over-expression was negatively correlated with the histological grade (P = 0.0016). These results have been published previously (Fig. 2) .
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RELATIONSHIP BETWEEN BCL6 GENE MUTATION AND BCL6 PROTEIN OVER-EXPRESSION
Of the 21 TCCs with BCL6 gene mutation, 10 (47.6%) showed BCL6 protein overexpression, and of the 26 TCCs without BCL6 gene mutation, 11 (42.3%) had protein over-expression. Therefore, there was no correlation between over-expression of BCL6 protein and the BCL6 gene mutation at the 5′ non-coding region (Table 2) . Although the over-expression rate of BCL6 protein was higher in the TCCs with BCL6 gene mutation at fragment E1.12 compared with TCCs without the BCL6 gene mutation at fragment E1.12, this difference was not statistically significant.
Discussion
The BCL6 protein is among the Kruppel-like subfamily of zinc finger proteins, and may function as a DNA-binding transcription factor that regulates organ development as described expression of the BCL6 protein independent of BCL6 gene alterations in T-cell lymphomas. In this study there was no correlation between the BCL6 gene mutation at the 5′ non-coding region and its protein expression in TCC. Therefore, mechanisms other than mutation of the gene may lead to dysregulated gene expression, and BCL6 protein expression might occur as a consequence of dysregulation of the translation process.
In conclusion, the BCL-6 gene mutation and its protein over-expression were detectable in a large proportion of TCCs. BCL-6 protein over-expression as well as BCL-6 gene mutation of the E1.12 fragment may play an important role in morphologic differentiation of TCC.
